Fresh gene-disease links
When a new paper lands, past cases can be rechecked automatically against updated evidence.
Founded in Boulder, CO
The interpretation layer for genomic medicine.
Sequencing is solved. Interpretation is the bottleneck. Gamow Labs is building the AI-native approach that turns genomes and phenotypes into auditable clinical insight.
01 · The unkept promise
Genome sequencing got cheap. Answers did not.
The Human Genome Project promised a new era of diagnosis, prevention, and treatment. Sequencing costs fell by orders of magnitude, but every hard case still depends on a scarce web of analysts, counselors, physicians, and scientists.
Interpretation stayed slow, expensive, and concentrated in the few centers with specialist capacity. Gamow Labs exists to make that expertise abundant with machine intelligence.
Sequencing was never the crux. Interpretation is.
02 · What we built
An AI-native genomic interpretation agent.
Genome and phenotype in. Causative variant, clinical implications, and proposed treatment plan out, with ACMG-style confidence, auditable evidence, and a reasoning chain.
01
Ingest
The patient's whole genome and structured or unstructured clinical phenotype.
02
Reason
The agent weighs every variant against the evidence at machine scale.
03
Return
An ACMG-style clinical report with clear explanations and common treatment regimes.
03 · Living diagnosis
The genome is read once. The answer keeps improving.
Changing clinical picture
As symptoms emerge, the agent re-ranks variants against the updated patient profile.
Variant reclassification
Updated annotations flow into fresh interpretations without re-sequencing or manual restarts.
04 · Why now
Universal WGS works in academic NICUs. The system needs an engine to generalize to help all people.
CaliforniaProject Baby Bear saved $2.5M across 178 infants, with 43% diagnosed and hundreds of hospital days avoided.
FloridaProject Baby Manatee produced $2.9M net ROI and changed care for 19 of 20 diagnosed infants.
MichiganProject Baby Deer cut 214 hospital days and worked even at sites without an on-staff geneticist.
FederalH.R. 7118, introduced January 2026, would extend Medicaid coverage for children's genome sequencing nationwide.
05 · Validation
First clinical study: outperformed clinical labs.
In a blinded analysis of 66 alveolar capillary dysplasia cases called non-diagnostic by a number of clinical labs, Gamow Labs successfully identified a molecular explanation for all known cases and even solved two that had evaded human resolution for years (manuscript in review).
66
non-diagnostic cases re-analyzed in a blinded study
100%
of known cases given a molecular explanation
2
cases solved that had eluded experts for years